Synedica Cagri Reta

Synedica Cagri Reta is a dual-pen research product d 40mg and Cagrilintide 4mg. The Synedica product listing identifies Cagri Reta as a new two-pen kit, with one pen containing retatrutide 40mg and the second containing cagrilintide 4mg.

Cagri Reta brings together two investigational metabolic compounds with different biological mechanisms. Retatrutide is a triple receptor agonist targeting GIP, GLP-1 and glucagon receptors, while cagrilintide is a long-acting amylin analogue.

What Is Synedica Cagri Reta?

Synedica Cagri Reta is the product name used for a combination research kit containing:

• Retatrutide 40mg
• Cagrilintide 4mg
• Two separate pens
• Retatrutide pen
• Cagrilintide pen

The combination is positioned around research into complementary metabolic signaling pathways involving incretin, glucagon and amylin biology.

Synedica Cagri Reta 40mg + 4mg

The current Synedica catalogue specifies:

Pen 1: Retatrutide 40mg
Pen 2: Cagrilintide 4mg
Format: Dual injection pen kit
Product category: Metabolic research

The two compounds should be considered separate research materials rather than assuming that their individual clinical evidence establishes the safety or effectiveness of the combined Cagri Reta formulation.

Retatrutide and Cagrilintide

Retatrutide is an investigational triple agonist that acts on GIP, GLP-1 and glucagon receptors. Clinical research has investigated retatrutide in metabolic conditions including obesity and type 2 diabetes.

Cagrilintide is a long-acting amylin analogue being studied for its effects on amylin-related signaling, appetite pathways and metabolic regulation.

Combining these two research compounds creates a model for investigating multiple metabolic pathways simultaneously.

Synedica Cagri Reta Research Areas

Research involving the individual components may include:

• GIP receptor signaling
• GLP-1 receptor signaling
• Glucagon receptor activity
• Amylin receptor biology
• Appetite and satiety pathways
• Energy-balance research
• Glucose metabolism
• Metabolic pharmacology
• Peptide receptor research
• Multi-pathway metabolic signaling

Cagri Reta vs Cagri Sema

Cagri Reta and Cagri Sema are different combinations.

Cagri Reta:
Retatrutide 40mg + Cagrilintide 4mg

Cagri Sema:
Semaglutide 4mg + Cagrilintide 4mg

Synedica’s catalogue lists both products separately.

This distinction is particularly important for searchers comparing Synedica Cagri Reta, Cagri Reta, CagriSema, Cagrilintide, Retatrutide, and related research compounds.

Cagri Reta Research Status

Retatrutide and cagrilintide have each been studied independently, but the specific retatrutide + cagrilintide combination does not currently have the same clinical evidence base as CagriSema. Available evidence sources note that dedicated clinical trials of the precise retatrutide/cagrilintide combination have not established its clinical efficacy or safety.

Therefore, Cagri Reta should not be marketed using claims that the combination is an approved treatment or that its combined effects are clinically proven.

Synedica Cagri Reta Product Information

For research procurement, users should verify the exact product documentation for the relevant batch, including:

• Product composition
• Total peptide content
• Batch or lot information
• Certificate of analysis
• Identity testing
• Purity information
• Storage requirements
• Manufacturing documentation

Product specifications should always be confirmed against the current documentation supplied with the specific product.

Synedica Cagri Reta Specifications

Product: Synedica Cagri Reta
Format: Dual injection pen kit
Pen 1: Retatrutide 40mg
Pen 2: Cagrilintide 4mg
Components: Retatrutide + Cagrilintide
Research areas: Metabolic and peptide research
Status: Investigational research combination

Important Cagri Reta Notice

Synedica Cagri Reta should not be represented as an FDA-approved medication. Retatrutide remains investigational, and the specific combination of retatrutide with cagrilintide has not established the clinical evidence necessary to support treatment claims.

This information is provided for research and product-information purposes only. It is not medical advice and does not provide human dosing or treatment instructions.

Synedica Cagri Reta — Product Summary

Synedica Cagri Reta is a two-pen research kit containing Retatrutide 40mg and Cagrilintide 4mg. The product combines an investigational GIP/GLP-1/glucagon receptor agonist with a long-acting amylin analogue, creating a research model for investigating complementary metabolic signaling pathways.